University of Illinois at Chicago
Exemption #JDR449
Announcement of an Exempt Purchase
Award Info Published Wednesday March 5, 2025
McKesson Specialty HealthSpring, TX
- Amount: An estimated $999,000
- Terms: An estimated start date of 3/1/2025 through 6/30/2025
- Renewals: None
Summary
Vendors
1 total
0 BEP vendors
0 VBP vendors
0 Small businesses
The University award process may be delayed as this award goes through a state approval process.
First published Wednesday, March 5, 2025
The University awarded a contract for CAR-T therapy drug, Abecma.
Abecma is an immunological treatment that uses the body's own immune system to destroy cancerous cells. This treatment is used as a last option for patients who have failed previous cancer treatment.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical at a university-operated health care center or dispensary that provides care, treatment, and medications for students, faculty and staff (30 ILCS 500 / 1-13(b-5)) Without this drug, the Hospital will not be able to provide care for the patients and will lose revenue.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.